<DOC>
	<DOCNO>NCT02588183</DOCNO>
	<brief_summary>The COR advance study non-randomized prospective single center study assess result electrophysiologically guide approach PV cryoablation use Arctic Front Advance ST® catheter together Achieve® mapping catheter 25 patient drug-refractory paroxysmal AF . Methods Patient selection criterion original COR study . All patient follow Reveal LINQ® cardiac monitor implanted ablation . The primary objective proportion patient remain free atrial fibrillation recurrence without take antiarrhythmic drug 12 month ablation . Secondary objective : AF-free survival without anti arrhythmic drug 12 month ablation , cumulative AF burden ( number AF episodes percentage time AF ) 12 month ablation , percentage pulmonary vein bidirectional block end procedure , ablation time ( onset first energy delivery end last energy delivery ) , procedure time ( femoral puncture catheter removal ) , fluoroscopy time . Final result know 24 month first enrollment . Statistical analysis Continuous variable distribute normally accord Shapiro-Wilk test present mean [ standard deviation ] , value compare test . Continuous variable follow normal distribution present median [ 25th 75th percentile ] compare Mann-Whitney U test . Categorical variable two group expect value &lt; 5 compare Fisher exact test . Otherwise , categorical variable compare chi-squared test . The AF-free survival function represent Kaplan-Meier curve . Data analyse do JMP® ( version 9.0.1 , SAS Institute Inc. , Cary , NC , USA ) Stata® ( version 11.0 , StataCorp LP ; College Station , TX , USA ) .</brief_summary>
	<brief_title>PV Cryoablation Efficacy ( COR ADVANCE Study )</brief_title>
	<detailed_description>Background The Cryoenergy Or Radiofrequency [ COR ] trial randomize , single-center study compare efficacy anatomical simplify strategy pulmonary vein cryoballoon ablation ( 2 shot per PV , 1 first-generation Arctic Front® catheter per patient additional touch-up application close residual gap ) versus standard technique pulmonary vein isolation use open-irrigated radiofrequency catheter ( Navistar Thermocool® ) electrophysiological ( Lasso® ) electroanatomical guidance ( Carto 3® ) 50 patient drug-refractory paroxysmal atrial fibrillation . All patient follow implantable cardiac monitor ( Reveal XT® ) . The primary endpoint study ( proportion patient remain free atrial fibrillation recurrence without take antiarrhythmic drug 12 month ablation ) meet 48 % patient treat cryoenergy 68 % patient treated radiofrequency ( OR 0.43 [ 95 % confidence interval , 0.19 1.0 ] ; P=0.05 ) . This difference disappear adjustment acute procedural outcome . In patient 4 PVs block end procedure , difference group C group R primary endpoint ( 67 % versus 68 % ; P=0.94 ) . Thus , COR trial support : 1 ) complete PV conduction block critical success AF ablation ; 2 ) despite fact result anatomical cryoablation technique use COR study superior previously publish series patient treat PV cryoablation follow implantable monitor , result cryoablation might even well aim PV conduction block . At present time , availability Achieve® mapping catheter efficient 2nd-generation cryoballoon ArcticFront Advance® catheter provide opportunity test electrophysiologically guide PV cryoablation approach conventional PV isolation point-by-point radiofrequency ablation catheter . The COR advance study non-randomized observational prospective single center study assess result electrophysiologically guide approach PV cryoablation use Arctic Front Advance ST® catheter together Achieve® mapping catheter 25 patient drug-refractory paroxysmal AF . Methods Inclusion criterion : - Symptomatic recurrent paroxysmal AF - &gt; 2 episode last 6 month - Refractory 1 antiarrhythmic drug - Anatomical pattern consist 4 pulmonary vein - Willing capable providing inform consent Exclusion criterion : - Patients &lt; 18 &gt; 75 year old - Prior AF ablation - Prior cardiac surgery - Moderate severe valvular heart disease - Anteroposterior diameter leave atrium &gt; 50 mm - Hyperthyroidism , intracardiac thrombus , contraindication anticoagulation , concomitant acute illness , pregnancy . - Unavailability follow-up center least 1 year All procedure perform Arrhythmia Unit Institution . Patients need give write informed consent enrol study . Pre-procedural exams pre-ablation technique use COR trial . The end point PV cryoablation complete bidirectional PV conduction block assess Achieve® catheter . Only one ArcticFront Advance® ArcticFront Advance ST® catheter ( 23 28 mm diameter ) use per patient . Every cryoenergy delivery last 240 second , except case excessive freezing ( temperature ≤-65ºC 23 mm balloon ≤-60º 28 mm balloon ) , diaphragmatic hypokinesia significant adverse event relate freezing . No bonus application give time effect le 60 second 23-mm cryoballoon catheter , less 90 second 28-mm cryoballoon . When time effect assess , bonus application give provide complete occlusion PV freezing ( persistent contrast stain PV ) application result PV conduction block . Otherwise , either late PV conduction block incomplete PV occlusion freeze need bonus cryoenergy delivery . If PV conduction block achieve , one additional cryoenergy application give discretion responsible physician . Thus , number cryoenergy application limit protocol , use different size cryoballoon conventional point-by-point ablation catheter strongly discourage . Patient selection criterion original COR study . All patient follow Reveal LINQ® cardiac monitor implanted ablation . The primary objective proportion patient remain free atrial fibrillation recurrence without take antiarrhythmic drug 12 month ablation . Secondary objective : AF-free survival without anti arrhythmic drug 12 month ablation , cumulative AF burden ( number AF episodes percentage time AF ) 12 month ablation , percentage pulmonary vein bidirectional block end procedure , ablation time ( onset first energy delivery end last energy delivery ) , procedure time ( femoral puncture catheter removal ) , fluoroscopy time . Final result know 24 month first enrollment . Statistical analysis Continuous variable distribute normally accord Shapiro-Wilk test present mean [ standard deviation ] , value compare test . Continuous variable follow normal distribution present median [ 25th 75th percentile ] compare Mann-Whitney U test . Categorical variable two group expect value &lt; 5 compare Fisher exact test . Otherwise , categorical variable compare chi-squared test . The AF-free survival function represent Kaplan-Meier curve . Data analyse do JMP® ( version 9.0.1 , SAS Institute Inc. , Cary , NC , USA ) Stata® ( version 11.0 , StataCorp LP ; College Station , TX , USA ) .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Symptomatic recurrent paroxysmal AF &gt; 2 episode last 6 month Refractory 1 antiarrhythmic drug Anatomical pattern consist 4 pulmonary vein Willing capable providing informed consent Patients &lt; 18 &gt; 75 year old Prior AF ablation Prior cardiac surgery Moderate severe valvular heart disease Anteroposterior diameter leave atrium &gt; 50 mm Hyperthyroidism , intracardiac thrombus , contraindication anticoagulation , concomitant acute illness , pregnancy . Unavailability followup center least 1 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>atrial fibrillation</keyword>
	<keyword>catheter ablation</keyword>
	<keyword>pulmonary vein</keyword>
	<keyword>cryoenergy</keyword>
	<keyword>cryoablation</keyword>
	<keyword>ArcticFront</keyword>
</DOC>